Chemistry:MYCO-007

From HandWiki

MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.[1][2][3][4][5] It is a short-acting MDMA analogue.[2][4][5] MYCO-007 is being developed by Mydecine.[1] As of February 2024, it is in preclinical research.[1] The chemical structure of MYCO-007 does not yet appear to have been disclosed.[1] 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues[6][7][8]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "Delving into the Latest Updates on MYCO-007 with Synapse". https://synapse.patsnap.com/drug/849fd9074a27473293083fb5f81c3dbe. 
  2. ↑ 2.0 2.1 "Prospectus Supplement". Mydecine Innovations Group Inc.. 15 September 2023. https://sedar-filings-backup.thecse.com/00035993/2309151616480990.pdf. "MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug." 
  3. ↑ Mydecine Innovations Group (19 July 2022). "Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs". https://www.globenewswire.com/news-release/2022/07/19/2481634/0/en/Mydecine-Files-Full-Patent-Application-Covering-MYCO-006-Family-of-Novel-Short-Acting-MDMA-Analogs.html. "Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization." 
  4. ↑ 4.0 4.1 "Psilocybin Company Mydecine Is Down To $300k In Cash". 17 August 2022. https://www.greenmarketreport.com/psilocybin-company-mydecine-down-to-300k-in-cash/. "Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization." 
  5. ↑ 5.0 5.1 "Mydecine's MDMA with rapid onset and a short duration shows promising results". 24 April 2023. https://mugglehead.com/mydecines-mdma-with-rapid-onset-and-a-short-duration-shows-promising-results/. "The effects from the company’s MYCO-006 compounds last for only two hours and set in four times as fast [...] The biotech company announced the results of its preclinical mice studies on Monday examining its proprietary MDMA drug family MYCO-006. [...] MYCO-006 compounds have the same therapeutic effect as standard MDMA but have demonstrated a shorter half-life duration in animal research. The projected duration of the MYCO-006 compounds is around one to two hours, which is approximately one-third the length of the conventional six to eight hours for regular MDMA. Additionally, the onset of MYCO-006 compounds is expected to be four times faster than Gen-1 or regular MDMA. The drugs are intended to treat conditions such as PTSD, chronic pain, depression and addiction." 
  6. ↑ Hoyer DW, Roscow RF, Ling R, Gao C, "Novel short-acting psychoactive compounds of the mdma class", US patent 2024/0197679, published 20 June 2024
  7. ↑ "1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/169291098. 
  8. ↑ "1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/169291099. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MYCO-007&oldid=4176360"